Evidence map›Paper›PMID 39937352›Full record

ReviewCurrent oncology reports2025

Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder.

Lucas Motta Martinez, Lorena Cristina São Leão Ribeiro, Rodrigo Gilles Guidi, Caio Mazzonetto Teofilo de Moraes, Catharina Ribeiro Lyra, Bruno Liebl, Vinicius Henrique Almeida Guimarães, Richard Dobrucki de Lima, Lucas Schenk de Almeida, Caio Vinicius Suartz and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lucas Motta MartinezDivision of Urology, Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil.
Lorena Cristina São Leão RibeiroDivision of Urology, Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil.
Rodrigo Gilles GuidiDivision of Urology, Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil.
Caio Mazzonetto Teofilo de MoraesDivision of Urology, Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil.
Catharina Ribeiro LyraFederal University of Bahia, Salvador, Brazil.
Bruno LieblFederal University of Paraná, Curitiba, Brazil.
Vinicius Henrique Almeida GuimarãesDivision of Urology, Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil.
Richard Dobrucki de LimaDivision of Urology, Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil.
Lucas Schenk de AlmeidaDivision of Urology, Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil.
Caio Vinicius SuartzUrology Department, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
William Carlos NahasDivision of Urology, Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil.
Leopoldo Alves Ribeiro-FilhoDivision of Urology, Institute of Cancer of São Paulo, University of São Paulo, São Paulo, Brazil. leopoldofilho@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis narrative review aims to discuss the latest evidence for cell-free tumor DNA (ctDNA) use in bladder cancer, future perspectives and challenges in implementing this technology in clinical practice. RECENT

findingsRecent papers describe promising findings regarding ctDNA analysis in blood samples and in urine of bladder cancer patients. This biomarker can be used as a diagnostic tool, in prognostic evaluation and as additional data for treatment indication and surveillance.

Indexed as

Biomarkers, TumorCarcinoma, Transitional CellCirculating Tumor DNAUrinary Bladder NeoplasmsHumansPrognosisBiomarkers, TumorCirculating Tumor DNABladder cancerCell-free DNACirculating tumor DNAUrinary tumor DNAUrothelial carcinoma

Identifiers

PMID39937352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.